Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$39.0 million.

  • KalVista Pharmaceuticals' Net Cash Flow fell 54320.43% to -$39.0 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$29.8 million, marking a year-over-year decrease of 2809.86%. This contributed to the annual value of $97.8 million for FY2025, which is 52108.8% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Net Cash Flow stood at -$39.0 million for Q2 2025, which was down 54320.43% from $9.3 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' Net Cash Flow's 5-year high stood at $9.3 million during Q4 2024, with a 5-year trough of -$39.0 million in Q2 2025.
  • Its 3-year average for Net Cash Flow is -$7.6 million, with a median of -$58000.0 in 2024.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Net Cash Flow skyrocketed by 9916.1% in 2024, and later tumbled by 54320.43% in 2025.
  • Over the past 3 years, KalVista Pharmaceuticals' Net Cash Flow (Quarter) stood at $8.9 million in 2023, then increased by 5.27% to $9.3 million in 2024, then tumbled by 518.54% to -$39.0 million in 2025.
  • Its last three reported values are -$39.0 million in Q2 2025, $9.3 million for Q4 2024, and -$58000.0 during Q3 2024.